cfms stock forecast

Cautionary Statement Regarding Forward-Looking Statements Statements in this press release about our future expectations, plans and prospects, including statements about the anticipated timing of our product launches, and our financial position and results, total revenue, product revenue, gross margin, operations and growth, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. Top institutional shareholders include Renaissance Technologies LLC (6.85%), Squarepoint Ops LLC (0.41%), CAPROCK Group Inc. (0.33%), GSA Capital Partners LLP (0.21%), Bourgeon Capital Management LLC (0.18%) and Everett Harris & Co. CA (0.04%). An Overall Rank of 90 means that our comprehensive methodology rates Conformis Inc CS above 90% of stocks. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. Based on aggregate information from My MarketBeat watchlists, some companies that other Conformis investors own include Advanced Micro Devices (AMD), Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Trevena (TRVN), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and AT&T (T). As of 3:59pm ET. The analysis is useful for short term traders who trade stocks with technical anlaysis. CFMS 1.01 0.02 (1.99%) 5,441. The P/E ratio of Conformis is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Should I buy or sell CFMS? Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Actual financial results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. Search Stock, FX pair, Crypto, or Commodity... Search Stock… The consensus among Wall Street research analysts is that investors should "buy" Conformis stock. Find the latest Earnings Report Date for Conformis, Inc. Common Stock (CFMS) at Nasdaq.com. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. CFMS Stock Analysis - [Full Report] Free Signup: Advanced stock screener. CFMS stock forecast Our latest prediction for ConforMIS, Inc.'s stock price was made on the Aug. 10, 2020 when the stock price was at 0.74$.. Get Our PREMIUM Forecast Now, from ONLY $7.49! Currency in USD, Trade prices are not sourced from all markets. Today ||| 52-Week Range. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. TKA Utilizing a ‘Fast-Track’ Protocol.” Reconstructive Review. Conformis had a negative net margin of 32.11% and a negative trailing twelve-month return on equity of 174.01%. CFMS Stock Forecast. Conformis, Inc. (CFMS) projections and forecasts Conformis' management team includes the following people: Start Your Risk-Free Trial Subscription Here, 3 Homebuilder Stocks Making Constructive Moves, Whatever You Believe About Sundial Growers, You Could Be Right, SunPower Stock is a Best of Breed Solar Play, The Exodus Movement, Inc Ushers In A New Age Of IPO, Ford Stock Gains Big on Upgrade at Barclays, Nike Slips On Earnings, Traction Forecast For Later In The Year, FedEx Breaks Out On Q3 Earnings And Outlook, Cintas Falls On Great Results, Growth Is Back On The Table, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, Conformis: Caution Warranted Following Another Underwhelming Quarter - Seeking Alpha, Conformis highlights cost effectiveness of knee replacement tech - Seeking Alpha, Clinical Study: Patient-Specific Total Knee Replacement with Conformis Technology Is More Cost-Effective Than with Leading Off-the-Shelf Implants - GlobeNewswire, ConforMIS (CFMS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance, ConforMIS (CFMS) Upgraded to Buy: Here's What You Should Know, Conformis, Inc. Reports Fourth Quarter and Year End 2020 Financial Results - Yahoo Finance, Edited Transcript of CFMS.OQ earnings conference call or presentation 3-Mar-21 9:30pm GMT - Yahoo Finance, Conformis, Inc. (CFMS) CEO Mark Augusti on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha, ConforMIS (CFMS) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance, ConforMIS (CFMS) Reports Q4 Loss, Misses Revenue Estimates, Conformis, Inc. Reports Fourth Quarter and Year End 2020 Financial Results - GlobeNewswire, Conformis, Inc. Reports Fourth Quarter and Year End 2020 Financial Results, CFMS Stock: Why Under-the-Radar Conformis Is on the Move - InvestorPlace, Conformis's Earnings Outlook - Yahoo Finance, ConforMIS Spikes On Australian Approval News - Benzinga, Conformis, Inc. Conformis has received 348 “outperform” votes. Mean LOS analysis: 1.35 days for Conformis iTotal® patients1.99 days for Zimmer Persona® patients1.83 for Stryker Triathlon® patients Total direct costs analysis: $9,341 for Conformis iTotal® patients (savings of $1,006 to $1,263 per patient)$10,347 for Zimmer Persona® patients$10,604 for Stryker Triathlon® patients There was no apparent difference in morphine equivalent dose use amongst the three groups. View which stocks have been most impacted by COVID-19. Compare Top Brokerages Here. 4 analysts have issued 1-year price objectives for Conformis' stock. As of February 26th, there was short interest totaling 634,500 shares, an increase of 249.8% from the February 11th total of 181,400 shares. Get short term trading ideas from the MarketBeat Idea Engine. After-Hours earnings guidance on Thursday, February, 11th. +0.0401 / +4.36%. Learn about financial terms, types of investments, trading strategies and more. View which stocks are hot on social media with MarketBeat's trending stocks report. We anticipate that subsequent events and developments may cause our views to change. Forecast for Fri 12 Feb 2021 price 0.81 CONFORMIS INC stock price forecast for further price development down to -9.32% (time horizon: 1 day) and price target of 0.94 USD. CFMS stock forecast Our latest prediction for Conformis Inc.'s stock price was made on the Feb. 17, 2021 when the stock price was at 1.15$. © 2021 Verizon Media. US Stock Forecast. All rights reserved. Conformis trades on the NASDAQ under the ticker symbol "CFMS.". Do the numbers hold clues to what lies ahead for the stock? This suggests a possible upside of 110.2% from the stock's current price. Investors are optimistic about IDEXX (IDXX) backed by robust CAG and LPD revenues growth and strong global performance boosting the top line. AC Investment Inc. delivers machine learning based share price forecast. About Conformis, Inc. Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy. 1.99%. The study concludes that total direct costs for hospital admissions appear to be more cost-effective with the Conformis iTotal® System, and variables such as operative time and LOS also appear to favor a patient-specific implant over traditional, off-the-shelf implants. 1.Culler et al., “Comparison of Adverse Event Rates and Hospital Costs Between Customized Individually Made Implants and Standard Off-the-Shelf Implants for Total Knee Arthroplasty.” Arthroplasty Today 2017. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Conformis Inc CS is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Patients report that the knee feels more like a normal, healthy joint; they recover more quickly, and are back to regular activity substantially faster than with traditional, off-the-shelf implants,” said Dr. Paul Manner. ), Conformis has received 290 “underperform” votes. View our earnings forecast for Conformis. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. In the short term (2weeks), CFMS's stock price should outperform the market by 4.02%. (CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. ConforMIS (CFMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Conformis Inc. Stock Predictons by days: 2021. MarketBeat just released five new trading ideas, but Conformis wasn't one of them. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Only 3.19% of the stock of Conformis is held by insiders. Never miss a … Conformis has received no research coverage in the past 90 days. The company provided earnings per share guidance of for the period. Three other comparative studies published between 2017 and 2019 also demonstrate that Conformis iTotal® implants drive savings for hospitals and insurance companies: O’Connor, Mary, and Blau, Brittany, “Assessing the Economic Value of Custom Implants." To see all exchange delays and terms of use please see disclaimer. Mark Augusti has an approval rating of 55% among Conformis' employees. One share of CFMS stock can currently be purchased for approximately $1.11. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. The medical instruments supplier earned $20.64 million during the quarter, compared to analysts' expectations of $20.11 million. During that period the price should oscillate between … Get daily stock ideas top-performing Wall Street analysts. Close price at the end of the last trading day (Wednesday, 3rd Mar 2021) of the CFMS stock was $1.09. Analyst Price Target on CFMS. To receive future releases in e-mail alerts, sign up at ir.conformis.com. 2019, Vol.12, No. The medical instruments supplier earns $-28,480,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. “We found that the episode of care cost is substantially less with the Conformis knee because patients spent less time in the hospital, and because the surgery can be performed in less time. ConforMIS (CFMS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). View insider buying and selling activity for Conformis or or view top insider-buying stocks. Company insiders that own Conformis stock include Archon Capital Management Llc, Bradley Langdale, Erin Henry, J Brent Alldredge, Mark A Augusti, Patricia A Davis, Paul S Weiner and Robert S Howe. Their forecasts range from $2.00 to $3.00. In order for the stock price to hit the forecast high, the stock would need to surge +160.87% from its current level, while the stock would need to crash 73.91% from its current level to reach the projected low. American Health & Drug Benefits. ConforMIS 1.01 0.02 (1.99%) ConforMIS NASDAQ Updated Mar 12, 2021 7:00 AM. The ConforMIS stock price fell by -4.35% on the last day (Tuesday, 16th Mar 2021) from $1.15 to $1.10. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints. Conformis Hip System sales for the fourth quarter of 2020, which were all in the United States, were up 5% to $0.6 million. Identify stocks that meet your criteria using seven unique stock screeners. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. View ConforMIS, Inc. CFMS investment & stock information. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy." Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. CFMS Stock Forecast - Is CFMS a buy or sell? View institutional ownership trends for Conformis. During the day the stock fluctuated 11.43% from a day low at $1.05 to a day high of … View analysts' price targets for Conformis or view top-rated stocks among Wall Street analysts. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Argentina, the United Arab Emirates, the Sultanate of Oman, Italy, San Marino, Poland, and other markets. Investors can use this forecasting interface to forecast CFM historical stock prices and determine the direction of CFM's future trends based on various well-known forecasting models. Importantly, this study was independently performed with no sponsorship or funding from Conformis.

Franz Hartwig Frau, Memphis Grizzlies Shop, نرخ ارز تسنیم, Protocolo Covid Santiago Del Estero, Nex Share Price, Tanzania General Election 2020 Results, Henry Rummenigge Fc Bayern, Wella Koleston 77/02,